JPRN-UMIN000045784已完成Unknown
Verification of allergic symptom-improving effects and adequate safety in vivo by spraying and inhaling test aerosol - Verification of allergic symptom-improving effects and adequate safety in vivo by spraying and inhaling test aerosol
CPCC Company Limited0 个研究点目标入组 24 人开始时间: 2022年10月28日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Subjects with current/previous medical history of serious diseases in respiratory system. (2) Throughout this trial, subjects who take steadily in affecting medicines/foods/supplements. (3) Subjects being under some kind of medical treatment, or planning to be treated during this trial. (4) Subjects with previous/current medical history of serious diseases in heart, liver, kidney and/or digestive organs. (5) Subjects with excessive alcohol intake. (6) Pregnant, possibly pregnant, and lactating women. (7) Subjects having a drug/chemical allergy. (8) Subjects being under another clinical test with medicines and/or health foods, or participated in that within four weeks before this trial, or planning to take part in that after giving informed consent to participate in this trial. (9) Subjects who are planning to be treated for allergic rhinitis, and take steadily in antiallergic oral medicines, during this trial. (10) All the year around, subjects who take steadily in oral medicines, eye drops and nasal spray, corresponding to antihistamines and antiallergics. (11) Throughout this trial, subjects who have any difficulty in refraining from inhaling another antiseptic aerosol, which might affect the test results. (12) Subjects who donated their blood components and/or whole blood (200 mL) within a month to this trial. (13) Males who donated their whole blood (400 mL) within the last three months to this trial. (14) Females who donated their whole blood (400 mL) within the last four months to this trial. (15) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial. (16) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial. (17) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.
研究者
相似试验
进行中（未招募）
1 期
Observational study in allergic patients to treating hay fever against grass pollen.Patient reported outcome in patients treated with various doses of Depigoid Phleum.Allergic rhinitis/rhinoconjunctivitis with or without concomitant asthma due to grass pollen allergyMedDRA version: 14.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 14.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855MedDRA version: 14.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855EUCTR2013-004920-12-CZETI Pharma GmbH275
招募中
2 期
Verification of the effectiveness of allergen-containing processed foodsD005512Food AllergyJPRN-jRCTs041210080Kondo Yasuto60
已完成
Unknown
Clinical study on the allergic symptoms experienced after injection of SI-613/ONO-5704Osteoarthritis of knee and hip with history of administration of SI-613 / ONO-5704JPRN-jRCTs031220327Hayama Koremasa40
招募中
2 期
Subcutaneous immunotherapy with PROLINEM-DS-Asthma- Adults-Fase IIBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaRPCEC00000278ational Center of Bioproducts (BioCen)60
尚未招募
2 期
Effect of Talisadi Arka and Churna in Allergic Respiratory Tract DiseaseCTRI/2023/07/055367Dean and Principal of Parul Institute of Ayurved